Head Office +91 8729085230

Guru Angad Nagar,
New Delhi 110092

09.00 to 18.00 Monday to Saturday

Invasive extraintestinal pathogenic E.coli (ExPEC) disease Market Outline: 

The 9MM Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.

Invasive extraintestinal pathogenic E.coli (ExPEC) is the leading cause of UTIs infections, sepsis, and bacteremia especially in elderly patients. Invasive extraintestinal pathogenic E.coli is also considered as the leading cause of neonatal meningitis. Growing cases of antibiotic resistance, putting substantial burden on public health and economic.  ExPEC strains are highly susceptible to multidrug resistance, implicating in surging huge number of hospitalizations and mortality. It is estimated that more than 10 million deaths will be caused by antimicrobial resistance (AMR) by 2050. Even now global health care bodies have raised serious concerns regarding antimicrobial resistance (AMR) across major markets. 

Patients on antibiotics for a longer period, are more susceptible to get bacterial infections. Lack of substantial progress in the developments of novel antibiotics limiting treatment options. Thus, majority of the patients rely on already available antibiotics leading to large number of AMR case around the world. According to World bank estimates, AMR could result in approximately USD 1 trillion an additional healthcare cost burden by 2050, and US$ 1 trillion to US$ 3.4 trillion GDP losses per year by 2030

Report has Covered Granular-level Analysis in Each Mapped Market

Invasive extraintestinal pathogenic E.coli (ExPEC) disease Burden Analysis: (Result shown here is reflecting from studies meta-analysis, and CSP Analytics Solutions Analysis)

This section explored the epidemiology associated with Invasive extraintestinal pathogenic E.coli (ExPEC) disease

  • Extraintestinal pathogenic E. coli (ExPEC) causing XX million cases annually in the 9MM
  • XX million cases receiving treatment
  • Cases by causes type: 
    • Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million urinary tract infections (UTIs) cases annually in 9MM
    • Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million bloodstream infections (BSIs) cases annually in 9MM
    • Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million meningitis cases annually in 9MM 
    • Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million pneumonia cases annually in 9MM
  • Number of cases prevalent, annually diagnosed cases

Treatment Landscape: 

  • Treatment of invasive ExPEC disease requires holistic framework to address diverse set of patients accompanied with various therapeutic conditions (Co-morbidities). Collaboration among various specialties imperative to devise tailoring treatment plan. Efforts to promote antimicrobial stewardship and advocacy at patient and physician level is crucial approaches to mitigate the risk of antibiotic resistance in ExPEC strains.
  • Various treatment approaches involves while treating Invasive extraintestinal pathogenic E.coli (ExPEC) disease patients such as Antimicrobial Therapy, Surgical Intervention, Adjunctive Therapies, Follow-Up and Monitoring
  • Patients with co-morbidities and without co-morbidities are treated with different set of treatment. Specific treatment strategies tailored based on disease severity and co-morbid conditions 
  • Report explored, treatment strategies for different set of patients. What are the approaches embraced by physicians, while treating patients with co-morbidities and without co-morbidities
  • Invasive extraintestinal pathogenic E.coli (ExPEC) disease market is struggling to get an effective treatment
  • High spectrum antibiotics is currently the mainstay of therapy for patients
  • Recent clinical guidelines enable the streamlining the treatment approaches
  • Report, investigated patient segment targeted by each therapy type:
  • Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.

Report also examined Approaches for Management

  • First-line of therapy
  • Second-line of therapy
DrugTargeted Patient Segment
Antimicrobial TherapyXX
Supportive CareXX
Surgical InterventionXX
Adjunctive TherapiesXX
Follow-Up and MonitoringXX
                                                                                                   Targeted Respondents
Infectious Disease SpecialistsXX
General PhysicianXX
UrologistsXX
SurgeonsXX

Upcoming Therapy Assessment (Pipeline Analysis)

  • Report also provided promising therapy assessment including drugs, existing therapies, and upcoming therapy
  • Novel drug target assessment. For instance, development of vaccine-based therapy
  • Expected launch of key pipeline assets
  • Experts Opinion on the matter of accepting novel treatment options
  • Promising molecules advantages offer over existing therapy
  • Impact assessment of pipeline assets
  • Drug analogue analysis
  • Expected annual cost of therapy

 Market Segmentation Analysis by:

  • By Infections Type
    • Urinary Tract Infection’s
    • Blood Stream Infection’s
    • Meningitis
    • Pneumonia
  • By Patient
    • Pediatric
    • Adult
    • Elderly
  • By Treatment Type
    • Antibiotics
      • Empirical therapy
      • Targeted therapy
    • Vaccines
  • By Gender
    • Female
    • Male
  • By Route of Administration
    • Oral
    • Injectable
  • By Line of Therapy
    • First-line of therapy
    • Second-line of therapy

Market Dynamics: Explored in the report

  • Untreated Prevalent Pool of Invasive extraintestinal pathogenic E.coli (ExPEC) disease
  • Huge medical unmet need
  • Lack of specific treatment

Market Challenges: Explored in the report

  • Inadequate efficacious treatment options
  • Treating AMR cases
  • Research gap
  • Cost of therapy
  • Treatment compliance and adherence

Mapped Geography: Nine Major Markets (9MM) 

Report has fragmented the total market into five regions such as:

  • United States
  • 5-Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Rest of Europe
  • China
  • Japan
  • India
  • RoW (Rest of World)

 

Each mapped region has been examined at granular level based on below parameters:

  • United States Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
    • Market Size and Forecast Model 2023-2033
    • Disease Overview
    • Current Treatment Approaches
    • Key Opinion Leader (KOL) Views
    • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
    • Diagnosis and Treatment Guidelines
    • Drug Share Analysis (%)
    • Healthcare Provider Preferences (primary care physicians, infectious disease specialists, urologists, etc.)
    • Drug Treatment Adherence and Compliance Rate (%)
    • Annual Cost of Therapy
    • Market Unmet Need Analysis
  • 5-Europe Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
    • Market Size and Forecast Model 2023-2033
    • Disease Overview
    • Current Treatment Approaches
    • Key Opinion Leader (KOL) Views
    • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
    • Diagnosis and Treatment Guidelines
    • Drug Share Analysis (%)
    • Drug Treatment Adherence and Compliance Rate (%)
    • Annual Cost of Therapy
    • Current Treatment Landscape and Upcoming therapy Assessment
    • Market Unmet Need Analysis
    • Key Players in the Market and their Market share (%)
    • By Country
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
  • China Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
    • Market Size and Forecast Model 2023-2033
    • Disease Overview
    • Current Treatment Approaches
    • Key Opinion Leader (KOL) Views
    • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
    • Diagnosis and Treatment Guidelines
    • Drug Share Analysis (%)
    • Drug Treatment Adherence and Compliance Rate (%)
    • Annual Cost of Therapy
    • Current Treatment Landscape and Upcoming therapy Assessment
    • Market Unmet Need Analysis
    • Key Players in the Market and their Market share (%)
  • India Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
    • Market Size and Forecast Model 2023-2033
    • Disease Overview
    • Current Treatment Approaches
    • Key Opinion Leader (KOL) Views
    • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
    • Diagnosis and Treatment Guidelines
    • Drug Share Analysis (%)
    • Drug Treatment Adherence and Compliance Rate (%)
    • Annual Cost of Therapy
    • Current Treatment Landscape and Upcoming therapy Assessment
    • Market Unmet Need Analysis
    • Key Players in the Market and their Market share (%)
  • Japan Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
    • Market Size and Forecast Model 2023-2033
    • Disease Overview
    • Current Treatment Approaches
    • Key Opinion Leader (KOL) Views
    • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
    • Diagnosis and Treatment Guidelines
    • Drug Share Analysis (%)
    • Drug Treatment Adherence and Compliance Rate (%)
    • Annual Cost of Therapy
    • Current Treatment Landscape and Upcoming therapy Assessment
    • Market Unmet Need Analysis
    • Key Players in the Market and their Market share (%)
  • Rest of the World Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
    • Market Size and Forecast Model 2023-2033
    • Disease Overview
    • Current Treatment Approaches
    • Key Opinion Leader (KOL) Views
    • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
    • Diagnosis and Treatment Guidelines
    • Drug Share Analysis (%)
    • Drug Treatment Adherence and Compliance Rate (%)
    • Annual Cost of Therapy
    • Current Treatment Landscape and Upcoming therapy Assessment
    • Market Unmet Need Analysis
    • Key Players in the Market and their Market share (%)

Competitive Landscape (Existing and Pipeline Players): 

Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.

Companies Profile:

  • Sanofi
  • J&J Pharmaceuticals
  • Forge Therapeutics
  • Tetraphase Pharmaceuticals
  • Entasis Therapeutics
  • Nabriva Therapeutics
  • Polyphor
  • Cidara Therapeutics
  • Iterum Therapeutics
  • Others

Reason to buy this report:

  • Fostering Understanding on Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
  • In Order to Understand the Market Potential 
  • Opportunity Analysis (exist in the market for players)
  • Clinical Developments in the market
  • To Know Current and Future Market Trends
  • Key Players and their Key Strategic Move